Результаты поиска

The relationship between Long Noncoding RNA (lncRNA) Small Nucleolar RNA Host Gene 12 (SNHG12) expression in solid malignant tumors and prognosis of tumor patients: A systematic review and meta-analysis.

BackgroundSmall nucleolar RNA host gene 12 (SNHG12) has been demonstrated to be a long noncoding RNA (lncRNA) that facilitates the progression of several solid malignant tumors. However, whether the expression level of SNHG12 in solid malignant tumors is associated with patients prognosis have not been investigated.MethodsWe systematically searched PubMed, EMBASE and Cochrane Library from Jan 1, 1950 to Mar 24, 2020 for randomized controlled trials published in English on SNHG12 expression in solid malignant tumors. We used the Newcastle-Ottawa Scale to assess the quality of articles. The HRs

Как возраст при диагностике влияет на выживание миеломы? Эмпирические доказательства.

Предыстория/задачи: Неравенство в выживании нескольких миелом (ММ) происходит на основе таких факторов, как генетика, возраст, раса, уровень доходов и доступ к медицинскому обслуживанию. Влияние возраста при диагностике на выживание ММ не в полной мере понято и продолжает привлекать внимание исследователей. В этом исследовании изучается связь между возрастом при диагностике и результатами выживания с использованием данных из базы данных Центра медицинских наук Миэломы Университета Арканзаса (ММБР). Методы: Для анализа данных использовались кривые Каплан-Мейер и модели Кокса. В зависимости от в

Результаты октогенарских пациентов с множественной миеломой, лечившихся вне клинических исследований, с упором на терпимость и эффективность лечения.

Справочная информация: Данные о результатах лечения октогенианских пациентов с множественными миеломами (ММ), особенно при лечении за пределами клинических исследований, являются недостаточными. Цели и методы: MM pts ≥ 80 годы, лечение в ТАМСК с первой терапией между 2010 и 2023, были рассмотрены. Были проанализированы характеристики и результаты. Результаты: общее число 101 ПТ, из которых 54 мужчин с средним возрастом 84 годы80-98), были включены. Среди них 67.4% :: имел индекс коморбности Charlson ≥5, 37% имели ISS-3 (Международная система сборки) и 20% имели Revised-ISS-3. В нашем исследова

Проверка корейского инструмента гериатрической оценки у пожилых пациентов с множественной миеломой: многоцентральное исследование.

Цель Это исследование дает оценку корейской группе по изучению раковых заболеваний Score-7 (В тыс.KG-7) эффективность инструмента скрининга для пожилых пациентов с множественными миеломой (ММ) в целях предотвращения недосмотра и чрезмерной обработки. 100 Пожилые пациенты 70 и старше с недавно поставленным диагнозом MM, которые не прошли трансплантации с августа 2020 по январь 2022Средний возраст 77 годы и 73.0% Число пациентов, отнесенных к категории на этапах Международной системы уплотнения 2 или 3. Использование a 5-point отсечение KG-7 индекс (нежелезнодорожный, балл) ≥ 5Экспериментальное

Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Саркоидоз и повышенный риск сопутствующих заболеваний и смертности в Швеции.

ВВЕДЕНИЕ: Саркоидоз — это системное воспалительное заболевание с неясной этиологией, включающее образование гранулом. В большинстве случаев оно затрагивает легкие и лимфоузлы в грудной полости. Саркоидоз может протекать в острой или хронической форме, каждая из которых имеет различные клинические проявления и прогноз. МЕТОДЫ: Кейс-контрольное исследование коморбидности и морбидности у лиц, диагностированных с саркоидозом (код ICD10 D86) в Швеции с 2007 по 2016 год. Контроли были сопоставлены с случаями в соотношении 2:1 по возрасту, полу и району диагностики. Данные собрали из Шведского нацио

Venous thromboembolism in China: epidemiology, management strategies, and future directions.

Venous thromboembolism (VTE) is one of the leading causes of unexpected death among hospitalized patients. It is also a preventable condition, and its incidence can be substantially reduced through active and effective prophylaxis. In recent years, the burden of VTE in China has continued to increase, driven by population aging, a rising prevalence of malignancy, a growing volume of complex surgery, and advances in imaging and laboratory testing. At present, the clinical management paradigm for VTE in China has gradually evolved from the traditional acute event-centered 'diagnosis-treatment' p

Совпадение в полном тексте источника
… The first-in-human study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the factor XI monoclonal antibody SHR-2004 in healthy subjects Expert Opin Investig Drugs 33 2024 1075 1082 10.1080/13543784.2024.2391837 39166425 93 Bertoletti L. Escal J. Ozturk L. Geier M. … The emerging role of anticoagulants targeting factor XI in thromboembolism management Expert Rev Respir Med 19 2025 183 185 10.1080/17476348.2025.2467463 39943830 Funding This study is supported by the 10.13039/501100001809 National Natural Science Foundation of China ( 82470134 , 82103827 , 82470135 …

Advances in nanomaterial-mediated CRISPR/Cas delivery: from lipid nanoparticles to vesicle-derived systems.

Gene and genome editing therapies are increasingly connected with nanomaterials, which protect and transport fragile nucleic acids and CRISPR/Cas systems through biological barriers safely and accurately. This review discusses how different nanocarriers, including lipid-based, polymeric, inorganic, and vesicle-derived systems, can improve delivery efficiency, cell targeting, endosomal escape, and intracellular movement for gene and genome editing. It summarizes findings from early clinical and preclinical studies, comparing several carrier types such as ionizable lipid nanoparticles, polymeric

Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma.

The aim of the study was to evaluate the prognostic impact of minimal residual disease (MRD) in the real-world setting and the interaction between MRD and molecular risk, clinical response and autologous stem-cell transplant (ASCT). A retrospective analysis of 275 newly diagnosed multiple myeloma (NDMM) patients who achieved very good partial remission (VGPR) or better before maintenance were involved. We examined MRD status by multiparameter flow cytometry (MFC). At a median follow-up of 37 months (4-88 months), In patients who achieved ≥ VGPR, those with MRD negativity had significantly long

Microfluidic enrichment of plasma cells improves treatment of multiple myeloma.

Cytogenetic alterations form the basis for risk stratification for multiple myeloma (MM) and guide the selection of therapy; however, current pathology assays performed on bone marrow samples can produce false-negatives due to the unpredictable distribution and rarity of MM cells. Here, we report on a microfluidic device used to facilitate CD45 depletion to enhance the detection of cytogenetic alterations in plasma cells (PCs). Bone marrow samples from 48 patients with MM were each divided into two aliquots. One aliquot was subjected to classic flow cytometry and fluorescent in situ hybridizat

Первичное лечение нескольких пациентов, страдающих миэломой: оптимизация лечения пациентов в регионе Залива.

Варианты лечения недавно диагностированной миеломы (NDMM) значительно расширились за последние годы two десятилетиями, что привело к заметному улучшению показателей ответов и средней продолжительности жизни. Применительно к пациентам, имеющим на это право, аутологическая трансплантация стволовых клеток играет центральную роль в общей стратегии лечения, включающей индукцию, трансплантацию, консолидацию и техническое обслуживание. В этой статье мы почерпнули из нашего собственного коллективного клинического опыта лечения пациентов с NDMM в регионе Залива, чтобы обсудить стратегии лечения как име

Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma.

BackgroundThe treatment paradigm for multiple myeloma (MM) continues to evolve with the development of novel therapies and the earlier adoption of continuous treatments into the treatment pathway. Lenalidomide-refractory patients now represent a challenge with inferior progression free survival (PFS) reported to subsequent treatments. We therefore sought to describe the natural history of MM patients following lenalidomide in the real world.MethodsThis was a retrospective cohort review of patients with relapsed MM who received lenalidomide-based treatments in the U.K. Data were collected for d

FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy.

In December 2019, a novel SARS-CoV-2 coronavirus emerged, causing an outbreak of life-threatening pneumonia in the Hubei province, China, and has now spread worldwide, causing a pandemic. The urgent need to control the disease, combined with the lack of specific and effective treatment modalities, call for the use of FDA-approved agents that have shown efficacy against similar pathogens. Chloroquine, remdesivir, lopinavir/ritonavir or ribavirin have all been successful in inhibiting SARS-CoV-2 in vitro. The initial results of a number of clinical trials involving various protocols of administr

Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Relapsed/Refractory Multiple Myeloma: Results for Patients Aged <75 Years.

Background: The phase III ADMYRE trial evaluated plitidepsin plus dexamethasone (DXM) versus DXM alone in patients with relapsed/refractory multiple myeloma (r/r MM). ADMYRE met its primary endpoint, showing a 35% reduction in the risk of progression or death. Methods: Results from a pre-planned subgroup of patients aged <75 years are shown here. This subgroup includes most of the patients evaluated in the ADMYRE study: 145/171 patients (84.8%) in the plitidepsin + DXM arm and 71/84 (84.5%) patients in the DXM alone arm. Results: Compared to the overall ADMYRE population, a higher reduction wa

Плазма и вицеральный орган Kynurenin Metabolites Коррелат в Multical Sclerosis Cuprizon Animal Model.

Модель нескольких склерозов (MS) капризона (CPZ) является прекрасной для изучения молекулярных различий, связанных с ущербом, причиненным отравлением. Метаболические различия в кинуреньиновом пути (КП) разложения триптофана (TRP) наблюдаются как в MS, так и в модели мыши CPZ. Наша цель состояла в том, чтобы проанализировать кинуреньин, серотонин и индоловые пути деградации ТРП на периферии, в нейродегенеративных процессах воспаления. В нашем исследовании мыши питались 0,2% токсина CPZ в течение 5 недель. Мы изучили метаболиты на трех путях разрушения ТРП в моче, плазме и соответствующих висцер

An expanded nationwide view of chronic kidney disease in Aboriginal Australians.

We summarize new knowledge that has accrued in recent years on chronic kidney disease (CKD) in Indigenous Australians. CKD refers to all stages of preterminal kidney disease, including end-stage kidney failure (ESKF), whether or not a person receives renal replacement therapy (RRT). Recently recorded rates of ESKF, RRT, non-dialysis CKD hospitalizations and CKD attributed deaths were, respectively, more than sixfold, eightfold, eightfold and threefold those of non-Indigenous Australians, with age adjustment, although all except the RRT rates are still under-enumerated. However, the nationwide

Long non-coding RNAs in bone metastasis: progresses and perspectives as potential diagnostic and prognostic biomarkers.

In a precision medicine perspective, among the biomarkers potentially useful for early diagnosis of cancers, as well as to define their prognosis and eventually to identify novel and more effective therapeutic targets, there are the long non-coding RNAs (lncRNAs). The term lncRNA identifies a class of non-coding RNA molecules involved in the regulation of gene expression that intervene at the transcriptional, post-transcriptional, and epigenetic level. Metastasis is a natural evolution of some malignant tumours, frequently encountered in patients with advanced cancers. Onset and development of

Exploring the impact of m6A modification on immune diseases: mechanisms and therapeutic implication.

N6-methyladenosine (m6A) is a chemical modification of RNA and has become a widely discussed topic among scientific researchers in recent years. It is distributed in various organisms, including eukaryotes and bacteria. It has been found that m6A is composed of writers, erasers and readers and is involved in biological functions such as splicing, transport and translation of RNA. The balance of the human immune microenvironment is important for human health abnormalities. Increasing studies have found that m6A affects the development of immune diseases such as inflammatory enteritis and system

Anhydroicaritin suppresses tumor progression via the PI3K/AKT signaling pathway in hepatocellular carcinoma.

BackgroundHepatocellular carcinoma (HCC) is one of the most malignant tumors. The in vitro experiments on the application of Anhydroicaritin (AHI), the active ingredient of Bushen Huayu Decoction, in HCC treatment remain limited, particularly regarding its molecular mechanism.MethodsThe TCMSP platform was used for drug ingredient screening. The GeneCards database and DisGeNET database are used to collect liver cancer targets. PPI network construction of active component-target intersection target was completed with string database. The GO and KEGG pathway analyses were performed via bioinforma

Racial and ethnic differences in the utilization of autologous transplantation for lymphoma in the United States.

BackgroundRacial/ethnic disparities in the utilization of hematopoietic cell transplantation (HCT) have been reported for patients with hematologic malignancies, but population-based data are lacking for lymphoma patients. The objective of this study was to determine whether racial and ethnic disparities exist in the utilization of autologous HCT for lymphoma in the United States.MethodWe used Surveillance, Epidemiology, and End Results data linked to Medicare fee-for-service claims. We included Medicare beneficiaries aged 66+ years with Hodgkin or Non-Hodgkin lymphomas diagnosed between 2008